Novo Nordisk A/S

Eli Lilly and Company

Nestle S.A.

Diabetes and obesity drugs based on semaglutide and tirzepatide - Ozempic, Wegowy, Zepbound and other hits from Danish Novo Nordisk and U.S.-based Eli lilly - are not only affecting the pharmaceutical market, but also other industries, including food production, restaurants and even clothing sales. In June, The Wall Street Journal <a href="https://www.wsj.com/business/retail/ozempic-clothing-sizes-weight-loss-80f9f83d">reported</a> on the sudden demand for clothes in small sizes, one of the reasons for which was the widespread availability of new weight-loss drugs;

Business in the age of Ozempic: who will benefit from the growing popularity of weight loss drugs


Chewy, Inc.

Chewy is developing a chain of veterinary clinics and pet pharmacies, which will bring it additional revenue, according to BofA

Pandemic pets taken from shelters are aging out. Which company will capitalize on this?


ProKidney Corp.

Biotech ProKidney, which develops a cell therapy platform for the treatment of multiple chronic kidney diseases, rose sixfold yesterday, July 8, to reach a market capitalization of $1.8 billion. The trigger was successful clinical trial results of its drug, but analysts are cautious.&nbsp;

Biotech ProKidney soars 500% after positive trial results, but analysts are cautious

Hims & Hers Health, Inc.

Freedom Broker now recommends clients buy shares of Hims &amp; Hers Health, a telehealth company, in the wake of a recent dip. The mid-cap stock has lost 35% of its market value due to a canceled partnership with pharma giant Novo Nordisk, which alleges that Hims&nbsp;&amp; Hers put patient safety at risk through “deceptive” marketing and sold a knockoff version of its drug Wegovy. Despite this, Freedom Broker analysts think Hims &amp; Hers stock will bounce back quickly.&nbsp;

Freedom Broker says buy Hims & Hers after cancellation of tie-up with Novo Nordisk

Innovent Biologics is the first company in China to mount a real challenge to pharmaceutical giants Novo Nordisk and Eli Lilly in the obesity market. The approval of its weight loss drug opens a new chapter in the rapidly growing Chinese market, where local manufacturers are seeking to squeeze out foreign leaders with their expensive GLP-1 injections. What will the increased competition lead to and should the makers of Ozempic and Mounjaro be wary of the Chinese threat?

China approves Ozempic's first domestic competitor. What do investors need to know?

AstraZeneca PLC

At least a dozen companies are looking for a way to reduce muscle mass loss when taking weight loss drugs

Eli Lilly is entering a market valued at $30 billion, can it beat the competition?

Novo Nordisk's market value has fallen by nearly $400 billion in the ten months of the recession

Novo Nordisk shares recovered after the collapse. What will happen to the company next?

Shares of startup Verve soared more than 75% after the acquisition announcement


Eli Lilly will buy a genetic engineering startup. What signal does this send to investors?

Investors are hopeful that the company will be able to recover sales after the leadership change

Novo Nordisk regained its status as Europe's most valuable company on a day of falling markets

Danish drugmaker Novo Nordisk seeks new chief executive after share price slump

An activist investor has taken an interest in the manufacturer Ozempic. What is it known for?  

Alphabet Inc.

BioNTech SE

Tesla, Inc.

Daily review and forecast of events on the US stock market from&nbsp;Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

New York morning: focus on job stats, trade talks and new duties

LifeMD, Inc.

Quotes on the telehealth company LifeMD <a href="https://finance.yahoo.com/quote/LFMD/">jumped</a> more than 40% yesterday, April 29, after it announced that its platform would <a href="https://ir.lifemd.com/press-release-details.php?newsId=3070180">offer</a> one of the bestselling weight-loss drugs with no insurance approval required.

Pharmaceutical Companies